ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
80,775
-0,64%
Bitcoin
67 874,29
0,22%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sangamo Therapeutics Inc (SGMO)

  7. Sangamo Therapeutics Inc (SGMO) Actualités

SGMO

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SGMO
DateHeureSourceTitreSymboleSociété
29/05/202423h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
09/05/202422h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGMOSangamo Therapeutics Inc
09/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
09/05/202422h01Business WireSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
09/05/202414h05Business WireSangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingNASDAQ:SGMOSangamo Therapeutics Inc
02/05/202422h15Business WireSangamo Therapeutics Announces First Quarter 2024 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
22/04/202422h35Business WireSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)NASDAQ:SGMOSangamo Therapeutics Inc
22/03/202413h05Business WireSangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct OfferingNASDAQ:SGMOSangamo Therapeutics Inc
13/03/202413h05Business WireSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
13/03/202413h01Business WireSangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPsNASDAQ:SGMOSangamo Therapeutics Inc
12/03/202423h30Business WireSangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
12/02/202414h05Business WireSangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry DiseaseNASDAQ:SGMOSangamo Therapeutics Inc
06/02/202400h01Business WireSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety ProfileNASDAQ:SGMOSangamo Therapeutics Inc
26/01/202417h49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SGMOSangamo Therapeutics Inc
28/11/202322h14Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
01/11/202321h01Business WireSangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
25/10/202322h15Business WireSangamo Therapeutics Announces Third Quarter 2023 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
24/10/202308h01Business WireSangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)NASDAQ:SGMOSangamo Therapeutics Inc
20/09/202322h15Business WireSangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine SummitNASDAQ:SGMOSangamo Therapeutics Inc
08/08/202322h47Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SGMOSangamo Therapeutics Inc
08/08/202322h01Business WireSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
01/08/202322h15Business WireSangamo Therapeutics Announces Second Quarter 2023 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
20/07/202314h05Business WireSangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic EditingNASDAQ:SGMOSangamo Therapeutics Inc
17/07/202314h05Business WireSangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered CapsidsNASDAQ:SGMOSangamo Therapeutics Inc
29/06/202314h05Business WireSangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion DiseaseNASDAQ:SGMOSangamo Therapeutics Inc
26/06/202322h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGMOSangamo Therapeutics Inc
22/05/202314h05Business WireSangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry DiseaseNASDAQ:SGMOSangamo Therapeutics Inc
16/05/202314h00Business WireSangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical OfficerNASDAQ:SGMOSangamo Therapeutics Inc
02/05/202322h30Business WireSangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)NASDAQ:SGMOSangamo Therapeutics Inc
27/04/202301h05Dow Jones NewsStocks to Watch: Meta, Teradyne, United Rentals, Sangamo TherapeuticsNASDAQ:SGMOSangamo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SGMO

Dernières Valeurs Consultées

BIT
P1Q793
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés